Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 67.5% in September

Key Points

• Lonza Group's short interest significantly declined by 67.5% in September, with total shares short dropping from 11,700 to 3,800 as of September 30th.
• Zacks Research downgraded Lonza Group's rating from "strong-buy" to "hold" on September 22nd, although the overall average rating remains "Buy".
• The company's stock price recently increased by $1.22, reaching $70.04, with a 12-month trading range between $55.57 and $73.29.

Lonza Group Ag (OTCMKTS:LZAGY - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 3,800 shares, a decline of 67.5% from the September 15th total of 11,700 shares. Based on an average trading volume of 169,000 shares, the short-interest ratio is presently 0.0 days. Based on an average trading volume of 169,000 shares, the short-interest ratio is presently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded Lonza Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Lonza Group presently has an average rating of "Buy".

Lonza Group Price Performance

Shares of OTCMKTS LZAGY traded up $1.22 on Friday, hitting $70.04. The company had a trading volume of 49,049 shares, compared to its average volume of 88,649. Lonza Group has a 12-month low of $55.57 and a 12-month high of $73.29. The business has a 50 day moving average of $68.90 and a two-hundred day moving average of $68.73.

Lonza Group Company Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.